AstraZeneca Halts Distribution of COVID Vaccine | Armstrong Economics

At Extreme Investor Network, we strive to bring you the latest and most impactful information in the world of economics. Today, we want to discuss a recent development that has shaken the pharmaceutical industry and raised serious concerns about COVID-19 vaccines.

AstraZeneca, a British-Swedish pharmaceutical company, was recently forced to admit that its vaccine could produce lethal side effects, including Thrombocytopenic Syndrome (TTS), which can cause blood clots, internal bleeding, and even death. This revelation came to light amid a class action lawsuit in the UK, prompting AstraZeneca to pull its COVID mRNA experimental jab from shelves worldwide.

What is truly alarming is that the company, along with the World Health Organization and other health agencies, were aware of the risks associated with TTS, yet failed to inform the public. Questioning the safety of these vaccines was once met with social banishment, but now the truth is out in the open.

Related:  Biden Begins Buying Back Oil To Refill Strategic Reserve... Will Send Gas Prices Back To Record Highs

The European Union and Australia have taken action by repealing AstraZeneca’s marketing authorization and quietly removing the vaccine from their list of approved COVID vaccinations. Despite over 80 reported deaths in Britain alone due to side effects, AstraZeneca maintains that the vaccine is being pulled for “commercial reasons.”

As investors, it is crucial to monitor the actions of pharmaceutical companies like AstraZeneca, especially when it comes to their COVID treatments. The push for new and improved experimental concoctions raises questions about the true efficacy and safety of these vaccines.

The COVID-19 pandemic has undoubtedly eroded confidence in governments worldwide, as misinformation and deceit have led to untold suffering and loss of life. As we navigate through these uncertain times, we must remain vigilant and demand transparency from those in power.

Related:  Home Depot to Purchase SRS Distribution for $18.25 Billion in Move to Boost Pro Sales

At Extreme Investor Network, we will continue to provide you with insightful analysis and updates on the ever-evolving landscape of economics and finance. Stay informed, stay prepared, and together, we can weather any storm.

Source link